GeNeuro SA

Equities

GNRO

CH0308403085

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 03:00:07 2024-04-26 am EDT			5-day change	1st Jan Change
1.43 ^EUR	0.00%		0.00%	+31.19%

Mar. 20	Geneuro SA Announces Appointments of Board of Directors	CI
Feb. 02	GeNeuro: share price falls after private placement	CF

GeNeuro appoints new Chief Medical Officer

January 08, 2024 at 01:13 am EST

GeNeuro announces the appointment of Anke Post as Chief Medical Officer, effective last Friday, following the retirement of David Leppert, who had held this position since April 2020.

Following his retirement, David Leppert will continue to support the biopharmaceutical company as a consultant in its mission to introduce temelimab to multiple sclerosis patients.

Anke Post brings to GeNeuro her experience in neuroscience, psychiatry and neurology, as well as in the pharmaceutical industry. She has held senior positions at Novartis, Eli Lilly and Roche.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	NOVARTIS AG	89.5 CHF	-0.56%	+4.64%	200B
	GENEURO SA	1.43 EUR	0.00%	0.00%	45.18M

Latest news about GeNeuro SA

Geneuro SA Announces Appointments of Board of Directors	Mar. 20	CI
GeNeuro: share price falls after private placement	Feb. 02	CF
GeNeuro Raises EUR5 Million from Share Issue	Feb. 02	MT
GeNeuro appoints new Chief Medical Officer	Jan. 08	CF
Geneuro Sa Announces Executive Changes	Jan. 05	CI
GeNeuro: Citigroup Global Markets Ltd crosses the 5% threshold	Jan. 05	CF
GeNeuro: positive opinion for continuation of trial	Dec. 11	CF
GeNeuro's Mid-stage Study for Post-COVID Symptoms Therapy Gets Medical Committee's Nod	Dec. 11	MT
Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications	Dec. 11	CI
GeNeuro Finalizes Patient Enrollment in Early-stage Trial of Long-COVID Treatment	Nov. 28	MT
GeNeuro: end of recruitment for Covid long trial	Nov. 28	CF
GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024	Nov. 28	CI
GeNeuro and Verily Collaborate to Advance Long-COVID Research	23-10-19	CI
GeNeuro SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
GeNeuro in Collaboration with Heinrich-Heine University Announce Publication in PNAS of Results from their Joint Research on Role of HERV-W in MS	23-09-27	CI
GeNeuro: link established between Covid and HERV-W protein	23-09-11	CF
GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic Patients	23-09-11	CI
GeNeuro SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-05	CI
GeNeuro Lands EUR25 Million Loan to Advance Long COVID-19 Trial	23-03-07	MT
GeNeuro Begins Recruitment for Trial to Assess Temelimab's Efficacy as Therapy for Long COVID-19	22-11-16	MT
GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-Covid Assessing Temelimab	22-11-16	CI
Geneuro’S Protect-Ms Phase 2 Trial Data, Presented At the Ectrims 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in Ms	22-10-28	CI
GeNeuro Will Present Phase IIb Safety and Efficacy Data on Temelimab from its ProTEct-MS Study at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis	22-10-25	CI
GeNeuro SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-29	CI
GeNeuro SA Announces Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein and the Rationale for Targeted Therapy with Specific Antibody	22-08-30	CI

Chart GeNeuro SA

Duration

Period

More charts

Company Profile

GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.

Sector

Biotechnology & Medical Research

Calendar

2024-04-28 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.43 EUR

Average target price

4 EUR

Spread / Average Target

+179.72%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENEURO SA	+31.19%	45.18M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research